Infermedica vs Tempus AI
A detailed comparison to help you choose between Infermedica and Tempus AI.
🏆
Verdict: Tempus AI wins
Tempus AI scores 4.1/5, edging out Infermedica at 3.9/5. Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access.
Infermedica AI symptom checker and medical guidance | Tempus AI AI for precision medicine and clinical genomics | |
|---|---|---|
| Rating | 3.9 (1 review) | 4.1 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $500/mo | From $1000/mo |
| Best For | Healthcare organizations, insurers and digital-health platforms that need a certified, API-first triage and symptom-assessment engine to embed in their own patient front doors. | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | api accessteam features | ssoteam features |
| Visit Infermedica → | Visit Tempus AI → |
Infermedica
Pros
- + Form-based modality is CE-marked Class IIb medical device software under EU MDR 2017/745 and UK MHRA registered — a regulatory standing almost no competitor holds
- + Five-level triage output (emergency_ambulance through self_care) with alarming-symptom flags and evidence weighting that escalated my alarming test case while staying brief on a benign one
- + Two integration depths: stateful pre-built Platform API interviews (Triage, Intake, Follow-up) and a stateless Engine API for bespoke builds
- + 26 languages and three channels — chat with free-text understanding, voice for call centers, and structured form with body-avatar selection
- + Deterministic, explainable reasoning over a physician-verified knowledge base (160,000+ hours of clinician input claimed by the vendor) rather than open-ended LLM output
Cons
- - No public pricing, no free production tier, no self-serve trial — everything runs through demo and sales
- - Chat and voice modalities were not CE-marked at time of writing; only the form modality carries the Class IIb mark
- - Triage quality depends entirely on patient-reported evidence — misreported symptoms produce misrouted triage like any interview system
- - Organization-only product: no consumer app to buy, so individual clinicians cannot adopt it
- - Integration is a clinical-design project — connecting triage levels to real care capacity is left to the deploying organization
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Frequently Asked Questions
Which is better, Infermedica or Tempus AI?▼
Tempus AI scores higher at 4.1/5 vs 3.9/5 for Infermedica, making it the better-rated option in our comparison.
What is the difference between Infermedica and Tempus AI?▼
Infermedica: Infermedica provides clinical triage and symptom assessment through chat, voice or a call centre, guiding patients to the right level of care. Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties.
Is Infermedica or Tempus AI more affordable?▼
Infermedica starts at €500/mo, Tempus AI starts at €1000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.